Manifestations of Liver Impairment and the Effects of MH-76, a Non-Quinazoline α1-Adrenoceptor Antagonist, and Prazosin on Liver Tissue in Fructose-Induced Metabolic Syndrome.
fructose
hypertension
metabolic dysfunction-associated fatty liver disease
metabolic syndrome
α1-adrenoceptor antagonist
Journal
Metabolites
ISSN: 2218-1989
Titre abrégé: Metabolites
Pays: Switzerland
ID NLM: 101578790
Informations de publication
Date de publication:
03 Nov 2023
03 Nov 2023
Historique:
received:
21
09
2023
revised:
27
10
2023
accepted:
31
10
2023
medline:
24
11
2023
pubmed:
24
11
2023
entrez:
24
11
2023
Statut:
epublish
Résumé
Excessive fructose consumption may lead to metabolic syndrome, metabolic dysfunction-associated fatty liver disease (MAFLD) and hypertension. α1-adrenoceptors antagonists are antihypertensive agents that exert mild beneficial effects on the metabolic profile in hypertensive patients. However, they are no longer used as a first-line therapy for hypertension based on Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) outcomes. Later studies have shown that quinazoline-based α1-adrenolytics (prazosin, doxazosin) induce apoptosis; however, this effect was independent of α1-adrenoceptor blockade and was associated with the presence of quinazoline moiety. Recent studies showed that α1-adrenoceptors antagonists may reduce mortality in COVID-19 patients due to anti-inflammatory properties. MH-76 (1-[3-(2,6-dimethylphenoxy)propyl]-4-(2-methoxyphenyl)piperazine hydrochloride)) is a non-quinazoline α1-adrenoceptor antagonist which, in fructose-fed rats, exerted anti-inflammatory, antihypertensive properties and reduced insulin resistance and visceral adiposity. In this study, we aimed to evaluate the effect of fructose consumption and treatment with α1-adrenoceptor antagonists of different classes (MH-76 and prazosin) on liver tissue of fructose-fed rats. Livers were collected from four groups (Control, Fructose, Fructose + MH-76 and Fructose + Prazosin) and subjected to biochemical and histopathological studies. Both α1-adrenolytics reduced macrovesicular steatosis and triglycerides content of liver tissue and improved its antioxidant capacity. Treatment with MH-76, contrary to prazosin, reduced leucocytes infiltration as well as decreased elevated IL-6 and leptin concentrations. Moreover, the MH-76 hepatotoxicity in hepatoma HepG2 cells was less than that of prazosin. The use of α1-adrenolytics with anti-inflammatory properties may be an interesting option for treatment of hypertension with metabolic complications.
Identifiants
pubmed: 37999226
pii: metabo13111130
doi: 10.3390/metabo13111130
pmc: PMC10672990
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : National Science Center
ID : DEC-2014/15/D/NZ7/ 01807
Organisme : Jagiellonian University
ID : N42/DBS/000287
Références
Hepatology. 2005 Jun;41(6):1313-21
pubmed: 15915461
Cells. 2020 Feb 18;9(2):
pubmed: 32085378
JAMA. 1985 Aug 2;254(5):627-30
pubmed: 4009897
Nutrients. 2017 Sep 06;9(9):
pubmed: 28878197
Free Radic Biol Med. 2019 Aug 20;140:14-27
pubmed: 31201851
Gut Liver. 2016 Jan;10(1):101-8
pubmed: 26573293
Digestion. 2020;101(5):522-535
pubmed: 31600750
Acta Pharm Sin B. 2023 Jun;13(6):2403-2424
pubmed: 37425065
World J Hepatol. 2017 Jun 8;9(16):715-732
pubmed: 28652891
J Clin Invest. 1998 Jan 15;101(2):311-20
pubmed: 9435302
Front Pharmacol. 2016 Dec 20;7:495
pubmed: 28066244
Endocr Rev. 2019 Oct 1;40(5):1367-1393
pubmed: 31098621
Eur J Immunol. 1994 Sep;24(9):2237-42
pubmed: 7522168
Nutr Metab Cardiovasc Dis. 2006 Mar;16(2):137-47
pubmed: 16487914
Curr Hypertens Rep. 2023 Aug;25(8):151-162
pubmed: 37191842
Hepatology. 2023 Nov 20;:
pubmed: 37983810
Alcohol Clin Exp Res. 2012 Sep;36(9):1587-99
pubmed: 22413959
Anticancer Res. 2013 Nov;33(11):4695-700
pubmed: 24222103
World J Gastroenterol. 2014 Feb 21;20(7):1807-21
pubmed: 24587658
BMC Complement Altern Med. 2016 Mar 09;16:98
pubmed: 26961224
Pharmacol Res. 2018 Apr;130:438-450
pubmed: 29471102
J Hypertens. 2010 Sep;28(9):1796-803
pubmed: 20543713
Int J Mol Sci. 2021 Apr 19;22(8):
pubmed: 33921881
J Biochem Mol Toxicol. 2022 Jan;36(1):e22942
pubmed: 34725879
J Surg Res. 2015 Sep;198(1):99-107
pubmed: 26119275
Pharmaceuticals (Basel). 2021 Oct 25;14(11):
pubmed: 34832862
Nutr Metab Cardiovasc Dis. 2019 Jul;29(7):751-760
pubmed: 31133498
Nat Rev Gastroenterol Hepatol. 2018 Jan;15(1):11-20
pubmed: 28930295
Front Med (Lausanne). 2021 Mar 31;8:637647
pubmed: 33869251
Food Funct. 2014 Mar;5(3):587-97
pubmed: 24500568
PLoS One. 2014 Sep 03;9(9):e106563
pubmed: 25184237
Anat Rec (Hoboken). 2020 Jul;303(7):1747-1767
pubmed: 31581357
J Nutr. 2008 Aug;138(8):1452-5
pubmed: 18641190
Pharmacol Rep. 2013;65(1):173-8
pubmed: 23563035
Circulation. 2003 Jan 7;107(1):127-31
pubmed: 12515754
Nutrients. 2019 Aug 22;11(9):
pubmed: 31443567
Am Heart J. 2006 Nov;152(5):842-50
pubmed: 17070143
World J Gastroenterol. 2014 Nov 14;20(42):15539-48
pubmed: 25400438
Nutrients. 2017 Jan 31;9(2):
pubmed: 28146130
Anal Biochem. 1968 Oct 24;25(1):192-205
pubmed: 4973948
Biochem Biophys Res Commun. 2013 Aug 9;437(4):597-602
pubmed: 23850676
Int J Mol Sci. 2019 Jul 12;20(14):
pubmed: 31336820
Methods Enzymol. 1999;299:15-27
pubmed: 9916193
J Hepatol. 2011 Sep;55(3):654-659
pubmed: 21172393
Chest. 2000 Apr;117(4):1162-72
pubmed: 10767254
Eur J Pharmacol. 2021 Feb 15;893:173831
pubmed: 33359146
Hypertens Res. 2019 Aug;42(8):1125-1141
pubmed: 30872813
Prostate Cancer Prostatic Dis. 2002;5(2):88-95
pubmed: 12496995
Endocr Rev. 2020 Jan 1;41(1):
pubmed: 31629366
Metabolism. 2016 Aug;65(8):1049-61
pubmed: 26997538
Mech Ageing Dev. 2022 Jan;201:111617
pubmed: 34958827
Hepatology. 2008 Nov;48(5):1506-16
pubmed: 18924245
Br J Pharmacol. 2008 Feb;153(4):820-30
pubmed: 18071297
Arch Immunol Ther Exp (Warsz). 2013 Apr;61(2):119-25
pubmed: 23307037
Cardiovasc Res. 2006 Jul 1;71(1):118-28
pubmed: 16631627
Nutrients. 2021 Dec 27;14(1):
pubmed: 35010976
Xenobiotica. 2008 May;38(5):540-58
pubmed: 18421626
Curr Hypertens Rep. 2017 Oct 28;19(12):99
pubmed: 29080925
Pharmazie. 2011 Oct;66(10):733-9
pubmed: 22026152
Sci Rep. 2020 Aug 13;10(1):13671
pubmed: 32792584
Front Immunol. 2022 May 06;13:880298
pubmed: 35603224
Int J Mol Sci. 2021 Apr 16;22(8):
pubmed: 33923817
Front Pharmacol. 2021 Nov 18;12:783393
pubmed: 34867414
Biomed Pharmacother. 2021 May;137:111315
pubmed: 33561645
Gastroenterology. 2008 May;134(5):1369-75
pubmed: 18355813
Pharmaceuticals (Basel). 2021 May 18;14(5):
pubmed: 34069933